Tumour necrosis factor inhibitor-related lupus: safety of switching agents

被引：4

作者：

Luong, Jessica M. T. ^{[1
]}

Tan, Boon T. ^{[2
]}

Buchanan, Russell R. C. ^{[1
]}

Schachna, Lionel ^{[1
]}

机构：

[1] Austin Hlth, Dept Rheumatol, Heidelberg, Vic 3084, Australia

[2] Northern Hosp, Dept Dermatol, Epping, NSW, Australia

来源：

CLINICAL RHEUMATOLOGY | 2010年 / 29卷 / 05期

关键词：

Ankylosing spondylitis; Lupus; Switching; TNF inhibitors;

D O I：

10.1007/s10067-009-1365-y

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

An increase in reports of systemic lupus erythematosus (SLE) related to tumour necrosis factor inhibitor (TNFi) therapy has recently been highlighted. We report new-onset SLE in a 22-year-old woman after 13 months of infliximab for ankylosing spondylitis (AS). Lupus symptoms promptly resolved and serologic abnormalities improved after infliximab was ceased. A flare of AS symptoms after 2 months prompted cautious introduction of an alternative TNFi, etanercept. At 14 months follow-up, neither clinical nor serologic flare of lupus had occurred. To our knowledge, this is the third reported case of infliximab-related lupus that did not recur on switching to an alternative TNFi.

引用

页码：551 / 553

页数：3

共 10 条

[1] Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials [J].

Bongartz, T ;

Sutton, AJ ;

Sweeting, MJ ;

Buchan, I ;

Matteson, EL ;

Montori, V .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19) :2275-2285

[2] Drug-induced lupus due to anti-tumor necrosis factor α agents [J].

Costa, Michelle F. ;

Said, Nuha R. ;

Zimmermann, Bernard .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2008, 37 (06) :381-387

[3] Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy:: a French national survey [J].

De Bandt, M ;

Sibilia, J ;

Le Loët, X ;

Prouzeau, S ;

Fautrel, B ;

Marcelli, C ;

Boucquillard, E ;

Siame, JL ;

Mariette, X .

ARTHRITIS RESEARCH & THERAPY, 2005, 7 (03) :R545-R551

[4] Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another? [J].

Kocharla, L. ;

Mongey, A. B. .

LUPUS, 2009, 18 (02) :169-171

[5] MINOCYCLINE-RELATED LUPUS [J].

MATSUURA, T ;

SHIMIZU, Y ;

FUJIMOTO, H ;

MIYAZAKI, T ;

KANO, S .

LANCET, 1992, 340 (8834-5) :1553-1553

[6] Autoimmune diseases induced by TNF-targeted therapies -: Analysis of 233 cases [J].

Ramos-Casals, Manuel ;

Brito-Zeron, Pilar ;

Munoz, Sandra ;

Soria, Natalia ;

Galiana, Diana ;

Bertolaccini, Laura ;

Cuadrado, Maria-Jose ;

Khamashta, Munther A. .

MEDICINE, 2007, 86 (04) :242-251

[7] EPIDEMIOLOGY OF DRUG-INDUCED SYSTEMIC LUPUS ERYTHEMATOSUS [J].

SIEGEL, M ;

LEE, SL ;

PERESS, NS .

ARTHRITIS AND RHEUMATISM, 1967, 10 (05) :407-&

[8]

Thornhill J, 2008, RHEUMATOLOGY, V47, pII15

[9] Anti-TNF-induced lupus [J].

Williams, Emma L. ;

Gadola, Stephan ;

Edwards, Christopher J. .

RHEUMATOLOGY, 2009, 48 (07) :716-720

[10]

2009, AUSTR ADVERSE DRUG R, V28, P10

← 1 →